Tyra Biosciences (TYRA) Other Accumulated Expenses (2020 - 2026)

Tyra Biosciences has reported Other Accumulated Expenses for 7 years, with the latest figure at $15.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 33.62% year-over-year to $15.1 million; the trailing twelve-month figure through Mar 2026 stood at $15.1 million (up 33.62% YoY), and the FY2025 full-year result was $16.4 million, up 20.98% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $15.1 million, down from $16.4 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $16.4 million in Q4 2025, with the low at $2.3 million in Q1 2023.
• Historically, Other Accumulated Expenses has averaged $8.4 million across 5 years, with a median of $8.4 million in 2024.
• The largest YoY upside for Other Accumulated Expenses was 194.11% in 2023 against a maximum downside of 34.09% in 2023.
• Tyra Biosciences' Other Accumulated Expenses stood at $4.4 million in 2022, then soared by 135.3% to $10.4 million in 2023, then jumped by 30.81% to $13.6 million in 2024, then increased by 20.98% to $16.4 million in 2025, then retreated by 8.02% to $15.1 million in 2026.
• The last three Other Accumulated Expenses figures came in at $15.1 million (Q1 2026), $16.4 million (Q4 2025), and $13.4 million (Q3 2025), per Business Quant data.